KZIA - ノボゲン (Kazia Therapeutics Limited) ノボゲン

 KZIAのチャート


 KZIAの企業情報

symbol KZIA
会社名 Kazia Therapeutics Ltd (ノボゲン)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Miscellaneous  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カジア・セラピュティクス(Kazia Therapeutics Limited)(旧名:Novogen Limited)はがん治療の開発に従事するオンコロジーバイオテクノロジー会社である。同社は主に医薬品の研究・開発を行う。同社はスーパーベンゾピラン(SBP)技術および抗トロポミオシン(ATM)2つの医薬プラットフォームを有する。そのプラットフォームは多様な腫瘍学的適応症にわたり各種の薬物候補を産生する。同社の製品候補には、Cantrixil(TRX-E-002-1)、Anisina(ATM-3507)、Trilexium(TRX-E-009-1)がある。Cantrixilの適応症は卵巣がんであり、Trilexiumの適応症はびまん性真性中枢神経膠腫(DIPG)である。Anisinaの最初の標的小児適応症は神経芽腫である。CantrixilはSBP技術から生まれたリード開発候補者である。Anisinaは、癌細胞のアクチン細胞骨格を標的とする化学療法へのアプローチである。Trilexium(TRX-E-009-1)は、SBPの第2候補薬候補である。   ノボゲンはオ―ストラリアの製薬会社。主に、がんや更年期障害などの治療薬の開発に従事。原子や化学構成成分を使用してベンゾピラン分子骨格に基づく化合物を構築する。ス―パ―ベンゾピランの搾取の早期段階にある。製薬候補の「Trilexium」は、卵巣がんと多形性膠芽腫を対象にした治療薬である。   
本社所在地 Level 5 20 George St Hornsby New South Wales 2077 AUS
代表者氏名 James B. Garner ジェームズ・B・ガーナー
代表者役職名 Chief Executive Officer Executive Director
電話番号 +61 2-9878-0088
設立年月日
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.novogen.com
nasdaq_url https://www.nasdaq.com/symbol/kzia
adr_tso 1742974
EBITDA EBITDA(百万ドル) -7.60277
終値(lastsale) 3.1056
時価総額(marketcap) 5412980.0544
時価総額 時価総額(百万ドル) 13.23090
売上高 売上高(百万ドル) 0.08485
企業価値(EV) 企業価値(EV)(百万ドル) 8.99009
当期純利益 当期純利益(百万ドル) -4.29995
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Kazia Therapeutics Ltd (ADR) revenues decreased 52% to A$119K. Net loss decreased 43% to A$6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative expense decrease of 28% to A$5.6M (expense) Research and development expense decrease of 12% to A$9.8M (expense).

 KZIAのテクニカル分析


 KZIAのニュース

   Kazia Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/12/31 14:10:00 Stock Market Daily
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial  2020/12/09 00:25:31 Finance News Network
09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
   Kazia Therapeutics - Phase IIa shows good safety, consistent efficacy  2020/12/02 17:19:15 Edison Group
Kazia presented the results from a new interim data analysis of its ongoing Phase IIa study of paxalisib in glioblastoma multiforme (GBM). The data were consistent with previous data and showed progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. Importantly, Kazia also published some of the first safety data at the full 60mg dose, which show an attractive profile compared to other members of this class.
   Kazia Therapeutics Wall street estimates Earnings report Stock market Insights & financial analysis  2020/11/26 16:45:00 Stock Market Daily
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   Kazia Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/12/31 14:10:00 Stock Market Daily
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial  2020/12/09 00:25:31 Finance News Network
09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
   Kazia Therapeutics - Phase IIa shows good safety, consistent efficacy  2020/12/02 17:19:15 Edison Group
Kazia presented the results from a new interim data analysis of its ongoing Phase IIa study of paxalisib in glioblastoma multiforme (GBM). The data were consistent with previous data and showed progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. Importantly, Kazia also published some of the first safety data at the full 60mg dose, which show an attractive profile compared to other members of this class.
   Kazia Therapeutics Wall street estimates Earnings report Stock market Insights & financial analysis  2020/11/26 16:45:00 Stock Market Daily
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.
   Kazia Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/12/31 14:10:00 Stock Market Daily
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial  2020/12/09 00:25:31 Finance News Network
09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
   Kazia Therapeutics - Phase IIa shows good safety, consistent efficacy  2020/12/02 17:19:15 Edison Group
Kazia presented the results from a new interim data analysis of its ongoing Phase IIa study of paxalisib in glioblastoma multiforme (GBM). The data were consistent with previous data and showed progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. Importantly, Kazia also published some of the first safety data at the full 60mg dose, which show an attractive profile compared to other members of this class.
   Kazia Therapeutics Wall street estimates Earnings report Stock market Insights & financial analysis  2020/11/26 16:45:00 Stock Market Daily
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted  2020/11/18 12:29:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Insmed Incorporated (NASDAQ: INSM ) Keros Therapeutics Inc (NASDAQ: KROS ) Kymera Therapeutics Inc (NASDAQ: KYMR ) LeMaitre Vascular Inc (NASDAQ: LMAT ) NeoGenomics, Inc. (NASDAQ: NEO ) Neuronetics Inc (NASDAQ: STIM ) Outset Medical Inc (NASDAQ: OM ) Prelude Therapeutics Inc (NASDAQ: PRL ) PTC Therapeutics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノボゲン KZIA Kazia Therapeutics Limited)

 twitter  (公式ツイッターやCEOツイッターなど)